NCT06084663View on ClinicalTrials.gov

Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

February 25, 2023

Study Completion Date

April 25, 2023

Conditions
Psoriasis and Psoriatic Arthritis
Interventions
DRUG

Apremilast 30 mg Tablets

Each film-coated tablet contains 30 mg of apremilast

DRUG

Otezla 30 mg film-coated tablets

Each film-coated tablet contains 30 mg of apremilast

Trial Locations (1)

382481

Lambda Therapeutic Research Ltd., Ahmedabad

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY